Skip to main content

Foley & Lardner LLP represented TCG Crossover as the lead investor in KalVista Pharmaceuticals’ $58 million registered direct offering.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

The company intends to use the proceeds of this $58 million offering to fund clinical trials, commercial sales development, research, working capital, capital expenditures, and other general corporate purposes. KalVista Pharmaceuticals, Inc. is listed on the Nasdaq under the trading symbol KALV.

TCG Crossover is a science-driven investment firm dedicated to advancing disruptive medicines, supporting private and public companies building the future of medicine.

The Foley team was led by Partners Louis Lehot and Clyde Tinnen.

About Foley’s Life Sciences Team

Foley’s Life Sciences Team is composed of corporate, health care, regulatory and IP attorneys. From fluctuating global financial markets and a rapidly changing IP environment to regulatory hurdles that can affect the products you bring to market, the life sciences industry poses challenges to start-ups and established enterprises alike. For decades, our attorneys have been partnering with life sciences companies at all stages of development to help them make their mark on the industry.  The team supports founders, entrepreneurs, and investors with the tools they need to launch their business toward growth, no matter the stage.

Author Louis Lehot

More Insights by Louis Lehot